首页> 外文学位 >Engineering lentiviral vectors for gene therapy and development of live cell arrays for dynamic gene expression profiling.
【24h】

Engineering lentiviral vectors for gene therapy and development of live cell arrays for dynamic gene expression profiling.

机译:用于基因治疗的工程慢病毒载体,以及用于动态基因表达谱分析的活细胞阵列的开发。

获取原文
获取原文并翻译 | 示例

摘要

With their advantages including wide tropism, high efficiency in gene transfer to both dividing and non-dividing cells, and stable and long-term expression of transgenes, lentiviral vectors have been attractively used for genes therapies and widely used for basic biomedical researches where gene transfer is required. As expression of multiple genes from the same target cell is required in such applications, this research work focused on designing novel multicistronic lentiviral vectors to develop gene therapy of diabetes through regulated insulin delivery from skin cells and live cell arrays for analyzing gene expression in a high-throughput and real-time manner. Specifically, first, lentiviral vectors were engineered to produce a fusion protein between the furin cleavable proinsulin gene and the self-dimerization mutant of FK506-binding protein to yield bioactive insulin in keratinocytes that could be released following exogenous administration of a small organic molecule, rapamycin. The engineered keratinocytes retained normal morphology and grew similar to lentiviral-treated control cells. Epidermal keratinocytes in culture and in stratified bioengineered epidermis released insulin within 30 min after addition of rapamycin, and secretion slowed or stopped within 2-3 hours after removal of the inducer. When the cells were implanted into athymic mice that were rendered diabetic with streptozotocin, insulin was detected in the plasma within 1 hr after addition of rapamycin. Concomitantly, glucose decreased to normal levels even in diabetic animals suffering severe hyperglycemia. Repeated rapamycin administration yielded similar results. These experiments provide proof-of-concept that insulin released from the skin in a regulatable manner can be an effective treatment for diabetic patients.;Second, a lentiviral vector carrying two transcriptional units was designed to reach independent and high level dual-gene expression. The two transcriptional units were separated by polyadenylation, terminator and insulator sequences in order to eliminate promoter interference existing between the transcriptional units. With this design, the expression level of both genes was as high as that yielded from lentiviral vectors containing only a single transcriptional unit. Similar results were observed with several promoters and cell types including epidermal keratinocytes, bone marrow mesenchymal stem cells and hair follicle stem cells. Notably, this research work also demonstrated quantitative dynamic monitoring of gene expression in primary cells with no need for selection protocols suggesting that this optimized lentivirus may be useful in high-throughput gene expression profiling studies.;Last, using the novel double-promoter lentiviral vector scalable live-cell microarrays were developed to measure gene expression dynamics in a real-time and high-throughput manner. To this end, dual-promoter lentiviral vectors were prepared harboring a transcriptional regulatory element encoding for green fluorescence protein to monitor cell activation in response to exogenous stimuli and a constitutive promoter driving red fluorescence protein for internal signal normalization. Lentivirus preparations were immobilized in a microarray format and after transduction on the array surface target cells were treated with cytokines and interrogated in real-time using automated fluorescence microscopy, providing rich dynamic information over a period of several days. Data normalization by red fluorescence intensity eliminated errors due to spot-to-spot variability in transduction efficiency or changes in cell proliferation upon cytokine treatment. These results suggest that the LVA can monitor gene expression in real-time and high-throughput manner thereby providing a useful tool for quantitatively measuring gene expression dynamics and deciphering gene regulatory networks.
机译:慢病毒载体具有广泛的嗜性,向分裂和非分裂细胞的高效基因转移以及稳定和长期表达转基因的优势,已被有吸引力地用于基因治疗,并广泛用于基因转移的基础生物医学研究是必须的。由于在此类应用中需要来自同一靶细胞的多个基因的表达,因此本研究工作集中于设计新型多顺反子慢病毒载体,以通过从皮肤细胞和活细胞阵列中调节胰岛素的递送来开发糖尿病的基因疗法,从而分析高水平的基因表达。吞吐量和实时方式。具体而言,首先,将慢病毒载体工程化,以产生弗林蛋白酶可裂解的胰岛素原基因与FK506结合蛋白的自二聚体突变体之间的融合蛋白,从而在角质形成细胞中产生生物活性胰岛素,该外源性有机小分子雷帕霉素外用后可释放出该蛋白。工程化的角质形成细胞保留了正常的形态,并与慢病毒治疗的对照细胞相似地生长。加入雷帕霉素后,培养物中和分层生物工程表皮中的表皮角质形成细胞在加入雷帕霉素后30分钟内释放胰岛素,在去除诱导剂后2-3小时内分泌减慢或停止。当将细胞植入使用链脲佐菌素治疗糖尿病的无胸腺小鼠中时,在添加雷帕霉素后1小时内血浆中就检测到胰岛素。同时,即使在患有严重高血糖症的糖尿病动物中,葡萄糖也降至正常水平。雷帕霉素的重复给药产生相似的结果。这些实验提供了概念上的证明,即以可调节的方式从皮肤释放的胰岛素可以是糖尿病患者的有效治疗方法。第二,设计带有两个转录单位的慢病毒载体以实现独立的高水平双基因表达。为了消除存在于转录单元之间的启动子干扰,通过聚腺苷酸化,终止子和绝缘子序列将两个转录单元分开。通过这种设计,两个基因的表达水平与仅包含单个转录单位的慢病毒载体的表达水平一样高。在几种启动子和细胞类型(包括表皮角质形成细胞,骨髓间充质干细胞和毛囊干细胞)中观察到了相似的结果。值得注意的是,这项研究工作还证明了对原代细胞中基因表达的定量动态监控,无需选择方案,这表明这种优化的慢病毒可能在高通量基因表达谱研究中有用。;最后,使用新型双启动子慢病毒载体开发了可扩展的活细胞微阵列,以实时,高通量的方式测量基因表达动态。为此,制备了双启动子慢病毒载体,其携带编码绿色荧光蛋白的转录调控元件以监测细胞响应于外源刺激的活化,以及组成型启动子驱动红色荧光蛋白用于内部信号归一化。慢病毒制剂以微阵列形式固定,并在转导到阵列表面后,用细胞因子处理靶细胞,并使用自动荧光显微镜实时询问,在几天内提供丰富的动态信息。通过红色荧光强度进行数据归一化消除了因转导效率的点对点差异或细胞因子处理后细胞增殖变化而引起的错误。这些结果表明,LVA可以实时和高通量的方式监测基因表达,从而为定量测量基因表达动态和破译基因调控网络提供了有用的工具。

著录项

  • 作者

    Tian, Jun.;

  • 作者单位

    State University of New York at Buffalo.;

  • 授予单位 State University of New York at Buffalo.;
  • 学科 Engineering Biomedical.
  • 学位 Ph.D.
  • 年度 2010
  • 页码 149 p.
  • 总页数 149
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 11:37:20

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号